Allopurinol Disease Interactions

There are 3 disease interactions with allopurinol:

Allopurinol (Includes Allopurinol) ↔ Dehydration

Moderate Potential Hazard, High plausibility

Applies to: Dehydration, Diarrhea, Vomiting

Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and the renal precipitation of urates when concomitant uricosuric agents are given. Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid. In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended. Maintenance of a slightly alkaline or neutral urine is also desirable.

References

  1. Stote RM, Smith LH, Dubb JW, Moyer TP, Alexander F, Roth JL "Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy." Ann Intern Med 92 (1980): 384-5
  2. McInnes GT, Lawson DH, Jick H "Acute adverse reactions attributed to allopurinol in hospitalized patients." Ann Rheum Dis 40 (1981): 245-9
  3. "Product Information. Zyloprim capsules (allopurinol)." Glaxo Wellcome, Research Triangle Park, NC.
View all 4 references

Allopurinol (Includes Allopurinol) ↔ Liver Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels. Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported. Therapy with allopurinol should be administered cautiously in patients with liver disease. Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.

References

  1. Raper R, Ibels L, Lauer C, Barnes P, Lunzer M "Fulminant hepatic failure due to allopurinol." Aust N Z J Med 14 (1984): 63-5
  2. Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG "Allopurinol hepatotoxicity." Ann Intern Med 95 (1981): 588-90
  3. "Product Information. Zyloprim capsules (allopurinol)." Glaxo Wellcome, Research Triangle Park, NC.
View all 4 references

Allopurinol (Includes Allopurinol) ↔ Renal Dysfunction

Moderate Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels. Therapy should be initiated at reduced dosages with smaller incremental changes in such patients. Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol. Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases. Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.

References

  1. Hande K, Reed E, Chabner B "Allopurinol kinetics." Clin Pharmacol Ther 23 (1978): 598-605
  2. Hande KR, Noone RM, Stone WJ "Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency." Am J Med 76 (1984): 47-56
  3. "Product Information. Zyloprim capsules (allopurinol)." Glaxo Wellcome, Research Triangle Park, NC.

You should also know about...

allopurinol drug Interactions

There are 134 drug interactions with allopurinol

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2014 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web1)